Cargando…
Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Università Cattolica del Sacro Cuore
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631717/ https://www.ncbi.nlm.nih.gov/pubmed/38028390 http://dx.doi.org/10.4084/MJHID.2023.061 |
| _version_ | 1785132422046679040 |
|---|---|
| author | Assanto, Giovanni Manfredi Totaro, Matteo Poggiali, Rebecca Delli Paoli, Adele Annechini, Giorgia D’Elia, Gianna Maria Aji, Francesco Petrucci, Luigi Fazio, Francesca Del Giudice, Ilaria Martelli, Maurizio Micozzi, Alessandra Gentile, Giuseppe |
| author_facet | Assanto, Giovanni Manfredi Totaro, Matteo Poggiali, Rebecca Delli Paoli, Adele Annechini, Giorgia D’Elia, Gianna Maria Aji, Francesco Petrucci, Luigi Fazio, Francesca Del Giudice, Ilaria Martelli, Maurizio Micozzi, Alessandra Gentile, Giuseppe |
| author_sort | Assanto, Giovanni Manfredi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10631717 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Università Cattolica del Sacro Cuore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106317172023-01-01 Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study Assanto, Giovanni Manfredi Totaro, Matteo Poggiali, Rebecca Delli Paoli, Adele Annechini, Giorgia D’Elia, Gianna Maria Aji, Francesco Petrucci, Luigi Fazio, Francesca Del Giudice, Ilaria Martelli, Maurizio Micozzi, Alessandra Gentile, Giuseppe Mediterr J Hematol Infect Dis Scientific Letter Università Cattolica del Sacro Cuore 2023-11-01 /pmc/articles/PMC10631717/ /pubmed/38028390 http://dx.doi.org/10.4084/MJHID.2023.061 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Scientific Letter Assanto, Giovanni Manfredi Totaro, Matteo Poggiali, Rebecca Delli Paoli, Adele Annechini, Giorgia D’Elia, Gianna Maria Aji, Francesco Petrucci, Luigi Fazio, Francesca Del Giudice, Ilaria Martelli, Maurizio Micozzi, Alessandra Gentile, Giuseppe Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study |
| title | Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study |
| title_full | Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study |
| title_fullStr | Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study |
| title_full_unstemmed | Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study |
| title_short | Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study |
| title_sort | impact of sars-cov-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with b-cell malignancies: a single-center retrospective study |
| topic | Scientific Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631717/ https://www.ncbi.nlm.nih.gov/pubmed/38028390 http://dx.doi.org/10.4084/MJHID.2023.061 |
| work_keys_str_mv | AT assantogiovannimanfredi impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT totaromatteo impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT poggialirebecca impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT dellipaoliadele impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT annechinigiorgia impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT deliagiannamaria impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT ajifrancesco impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT petrucciluigi impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT faziofrancesca impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT delgiudiceilaria impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT martellimaurizio impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT micozzialessandra impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy AT gentilegiuseppe impactofsarscov2prophylaxiswithtixagevimabcilgavimabinhighriskpatientswithbcellmalignanciesasinglecenterretrospectivestudy |